Research suggests a high proportion of melanoma in situ (MIS) may be overdiagnosed, potentially contributing to overtreatment, patient harm and inflated costs for individuals and healthcare systems. However, Australia-wide estimates of the magnitude of melanoma overdiagnosis are potentially outdated and there has been no estimation of the [...]
Adherence to self-management interventions is critical in both clinical settings and trials to ensure maximal effectiveness. This study reports how the Behaviour Change Wheel may be used to assess barriers to self-management behaviours and develop strategies to maximise adherence in a trial setting (the MEL-SELF [...]
In this article the Methods section of the Abstract was incorrectly given as “Economic costs were calculated alongside a randomised trial using standard cost analysis methodology from a societal perspective. Environmental impacts were calculated using a type of carbon footprinting methodology called process-based life cycle [...]
The objective of this study is to quantify the proportion of melanoma diagnoses (invasive and in situ) in the USA that might be overdiagnosed. In this ecological study, incidence and mortality data were collected from the Surveillance, Epidemiology and End Results 9 registries database. DevCan [...]
To the Editor: People with a history of melanoma have a higher risk of developing subsequent primary melanomas than the general population; however, a difference in outcome between those with multiple primary melanomas (MPMs) and a single primary melanoma (SPM) is not established. Using a [...]
Evidence indicates that a melanoma prevention program using personalized genomic risk provision and genetic counseling can affect prevention behaviors, including reducing sunburns in adults with no melanoma history. This analysis evaluated its longer-term cost-effectiveness from an Australian health system perspective.
The COVID-19 pandemic caused rapid implementation of telehealth for melanoma follow-up care in Australia. This study explores Australian melanoma patients and clinicians' level of satisfaction with telehealth.
Participants suggested that prerequisites for a reduction in routinely scheduled visits with melanoma doctors would include that sufficient time had elapsed since the previous diagnosis without a new primary melanoma or recurrence, an unscheduled appointment could be made at short notice if the patient noticed [...]
Adherence, both in research trials and in clinical practice, is crucial to the success of interventions. There is limited guidance on strategies to increase adherence and the measurement and reporting of adherence in trials of melanoma self-management practices.
Cancer screening aims to reduce morbidity and mortality through early detection of preclinical disease. These potential benefits must be weighed against potential harms from diagnostic procedures, induced anxiety, false-positive or false-negative results and the detection of ‘indolent’ cancers, otherwise known as overdiagnosis.